These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. Siegler RL; Pysher TJ; Tesh VL; Taylor FB J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574 [TBL] [Abstract][Full Text] [Related]
16. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome. Pysher TJ; Siegler RL; Tesh VL; Taylor FB Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894 [TBL] [Abstract][Full Text] [Related]
17. Treatment of typical (enteropathic) hemolytic uremic syndrome. Bitzan M; Schaefer F; Reymond D Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636 [TBL] [Abstract][Full Text] [Related]
18. Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease. Pradhan S; Pellino C; MacMaster K; Coyle D; Weiss AA Front Cell Infect Microbiol; 2016; 6():114. PubMed ID: 27747196 [TBL] [Abstract][Full Text] [Related]
19. Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. Zanchi C; Zoja C; Morigi M; Valsecchi F; Liu XY; Rottoli D; Locatelli M; Buelli S; Pezzotta A; Mapelli P; Geelen J; Remuzzi G; Hawiger J J Immunol; 2008 Jul; 181(2):1460-9. PubMed ID: 18606701 [TBL] [Abstract][Full Text] [Related]
20. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Liu F; Huang J; Sadler JE Blood; 2011 Sep; 118(12):3392-8. PubMed ID: 21816831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]